ABSTRACT. Microarray data were collected from bile duct samples from subjects with malignant biliary strictures by endoscopic retrograde cholangiopancreatography to screen for key genes associated with this disease. A predicted interaction network was constructed for these genes to interpret their functions. The gene expression dataset GSE34166 (10 samples: 6 malignant and 4 benign control samples) was downloaded from the Gene Expression Omnibus database. R package scripts were used to process the data and screen for differentially expressed genes. Genes identified were uploaded to the analysis tool String 8.3 to generate a gene interaction network. A hub gene was identified by calculating the node degree. The interaction network of the hub gene with other genes in the human genome was constructed and screened (score >0.9), and pathway-enrichment analysis was performed to elucidate the hub gene
INTRODUCTION
Biliary strictures consist of abnormal narrowing of bile duct and are the result of different causes, the most common of which is surgical injury to the bile duct. Other risk factors include cancer of the bile duct (Gamblin et al., 2009) , pancreatitis, and gallstones (Dooley, 2011) . The condition can be divided into benign and malignant biliary strictures, the latter of which results from primary or metastatic cancers.
Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive surgery method to examine the pancreatic duct and was developed by McCune in 1968. Since then, endoscopic drainage, biliary lithotomy, endoscopic pancreatic duct drainage, and embolization have also been developed (Nourallah et al., 1999; Lehman, 2002) . These new methods are used with additional techniques, such as high-frequency electric knife, laser, microwave, and electrohydraulic shock wave methods, which have further broadened the therapeutic range of ERCP. Today, ERCP is an important tool for diagnosing and treating pancreaticobiliary disease. Nevertheless, several risks remain especially serious postoperative complications that require vigilance in clinical practice.
With the recent advance of life science technologies for diagnosis and treatment of various tumor diseases, such as lung cancer, thyroid tumor, the use of genetics approaches has increasingly attracted attention (Bernig and Chanock, 2006; Garcia and Folpe, 2010) . Progress has also been made in detecting malignant biliary strictures. For example, previous studies have identified a point mutation in the KRAS gene that can be used for diagnosing malignant and benign biliary strictures. Nischalke et al. (2012) have shown that, in addition of cytology, the use of RT-PCR for measuring the expression of insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), HOXB7, and NIMA (never in mitosis gene A)-related kinase 2 (NEK2) genes improves the detection of malignant biliary disorders. Hass et al. (2008) have shown that osteopontin was the most consistently overexpressed gene in intrahepatic cholangiocarcinoma.
However, few studies have used high-throughput screening for and functional analysis of genes differentially expressed in malignant biliary strictures. To this end, we ana-
lyzed microarray data obtained from benign and malignant biliary stricture samples obtained by ERCP to identify hub and related genes through interaction network analysis by bioinformatic methods. These genes may be potential targets for future drug design or detection of cholangiocarcinoma.
MATERIAL AND METHODS

Microarray data
The data set GSE34166 (Chapman et al., 2012) , including raw files and probe annotations, was downloaded from the Gene Expression Omnibus (GEO) database, which contains 10 biliary stricture samples, representing 4 benign and 6 malignant tissues (cholangiocarcinoma). Chip data were acquired by using the GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. Probe annotation was obtained from Affymetrix that included information for all the probes on the Affymetrix ATH1 (25K) chip.
Data processing and identification of differentially expressed genes
Raw data were processed using the package Affy of R, including filling in of missing data with the KNN method (Marques et al., 2011) and data normalization with the median method (Fujita et al., 2006) . The LIMMA package (Smyth, 2005) was used to identify differentially expressed gene, followed by multiple-testing corrections with Bayesian methods (Benjamini and Hochberg, 1995) . A P value of <0.01 and fold-changes in expression of >2 or <-2 were used as cutoffs to identify differentially expressed genes.
Screening for hub genes
All genes identified as differentially expressed were uploaded to String (Szklarczyk et al., 2011) , to identify interactions between gene products using database information as well as characteristics of the input sequence. According to known protein interaction networks, most of them possess a scale-free property (Albert, 2005) , i.e., most nodes have only a few connections, and a few nodes in the network have a large number of connections. These few nodes are called critical network nodes (hub nodes). After the interaction network was generated, a node analysis was performed to screen of hub protein by using the scale-free property.
Construction of the interaction network for the hub gene
The hub gene was analyzed again by String to establish its predicted interaction network. Interaction pairs with score >0.9 were considered hub gene candidates.
Pathway-enrichment analysis
All of the genes in the predicted interaction network were uploaded to the DAVID software (Huang et al., 2009) , to calculate enriched pathways using hypergeometric distribution algorithm (false-discovery rate [FDR] <0.05 and count >2).
Hub gene-related transcription factors (TFs)
The DNA-binding domain in transcription factors binds to cis-acting elements in DNA sequences (Stower, 2011) , to inhibit or enhance gene expression. The text mining-based function of the free online tool EpiTect ChIP qPCR Primers (Han et al., 2010) was used to extract TFs of the hub gene from the published literature and other public resources.
RESULTS
Differentially expressed genes
Raw data were normalized (see Figure 1 ) and then screened for differentially expressed genes. In total, 377 differentially expressed genes were identified according to the pre-set criteria (P < 0.01, |logFC| > 1): 212 of these genes displayed down-regulated and 165 up-regulated expression. 
Screening for hub genes
The protein interaction network for the differentially expressed genes was generated using the String software and 209 pairs of interaction were identified. Topological analysis was performed on the network and showed a scale-free property (Figure 2) . Fitting of the power law generated the following equation: y = 117.8x
(-1.81) (see curve in Figure 2 ), wherein the x-axis is the node degree (k) and the y-axis is the number of nodes with degree k. As shown in figure, GSTA1 (9) had the highest number of nodes, indicating its important role in the network and suggesting that GSTA1 is a hub gene.
Determining the functions for the hub gene
The newly identified hub gene GSTA1 was set at the center to construct an interaction network consisting of 25 nodes against the background of the entire human genome ( Figure  3) . The differentially expressed gene GSTA3 was included in the network, whereas most of the other gene members belonged to the cytochrome P450 (CYP450) family. Distribution of node degree for the interaction network. The x-axis is the node degree (k), i.e., number of node directly connected to the specific node, and the y-axis is the number of node with degree k. The red line is a power function curve fitting the data points.
The 25 nodes were analyzed with the DAVID software, which uncovered 3 significantly enriched pathways (FDR < 0.05) (Table 1) , in which metabolism of exogenous chemicals by CYP450 was the most significant pathway. As shown in Figure 3 , most nodes interacting with GSTA1 and GSTA3 belonged to the CYP450 family. Thus, we speculate that the hub gene GSTA1 and the differentially expressed gene GSTA3 interact with CYP450 members and cause tumorigenesis through the pathways of exogenous metabolism by CYP450.
In addition, 4 transcription factors including Sp-1, Ap-1, c-Jun, and c-Fos that bind to the promoter of the key gene GSTA1 and their corresponding binding sites were identified (Figure 4) . Table 1 . Pathway-enrichment analysis result for all the genes in the predicted interaction network. FDR = false-discovery rate.
DISCUSSION
Our analysis of the chip data from cholangiocarcinoma tissues (Chapman et al., 2012 ) identified several differentially expressed genes, including GSTA1 and GSTA3. According to the network analysis, these two genes interacted with CYP450 members and thus participate in the CYP450 exogenous chemical metabolism.
Both GSTA1 and GSTA3 encode glutathione S-transferases (GST), which are involved in detoxification of electrophilic compounds, including drugs, toxins, and carcinogens, by conjugating these compounds with glutathione (Khan et al., 2011) . Kobayashi et al. (2000) reported a GST as a new sensitive marker of hepatocellular damage in biliary atresia, and Nakajima et al. (2003) reported that GST-pi is involved in resistance to anticancer drugs used for treating cholangiocarcinoma. Daorueang et al. (2012) uncovered the underlying mechanism for GST-promoted cell proliferation that accelerates the formation of cholangiocarcinoma.
CYP450 is a protein family widely distributed in human tissues and requires an iron porphyrin as prosthetic group. Most members are monooxygenases that catalyze a variety of metabolic reactions (Bruno and Njar, 2007) . The CYP450 superfamily can be broadly divided into two categories according to the metabolic substrates used: one contains P450s for the metabolism of endogenous compounds (such as steroids), and the other for the metabolism of exogenous substances (such as drugs, poisons, and carcinogens or mutagens). The pathway interacting with the hub gene is involved in oxidation, reduction of exogenous substances, as well as oxidative metabolism, and thus plays an important role in activating prodrugs or carcinogens or degrading drugs or poisons (Karlgren et al., 2006) . CYP450 enzymes frequently produce intermediates or final products that have strong affinities for electrons and these intermediates may interact with nucleophilic groups in intracellular macromolecules, such as DNAs, RNAs, or proteins. This may cause destruction of cell structures, enzyme inactivation, gene mutations, or suppression of gene expression, and ultimately result in cell damage, programmed death, or tumorigenesis (Iizasa et al., 2005) . Changes in CYP450 genes can lead to increased or decreased P450 activity or complete inactivation of the affected enzyme (Klotz, 2006) , and increased expression of CYP450 has been associated with cancer (Gharavi and El- Kadi, 2004; Bandala et al., 2012) . Several studies have reviewed the association of CYP450 polymorphisms with susceptibility to cancer (Han and Zhou, 2000; Sergentanis et al., 2012) , and because CYP450 enzymes are involved in the metabolism of many drugs, CYP450 activities have to be considered in the design of anticancer therapies (van Schaik, 2008) .
Because GSTA1, GSTA3, and CYP450 have similar functions, it is not unexpected that these proteins strongly interact with each other. Several studies have indicated that these proteins are involved in drug metabolism and are therefore associated with susceptibility to cancer (Forrester et al., 1990; Lin et al., 1998; Tan et al., 2000) and other diseases (Burim et al., 2004) . We believe that further studies are needed to investigate the associations between these proteins to improve our understanding of the mechanisms and processes underlying the formation of malignant biliary strictures.
In addition, TFs have attracted increasing attention because they are involved in regulating gene expression and thus play an important role in the onset, development, invasion, and metastasis of tumors. Because TFs are potential targets of new anticancer drugs (Darnell Jr., 2002) , we screened for the TFs that control expression of the GSTA1 gene and for their binding sites in the GSTA1 promoter. This analysis yielded identification of the 4 TFs including Sp1 (Ebert et al., 2003) , AP-1 (Romero et al., 2006) , c-Jun (Hayes and McMahon, 2001) , and c-Fos (Tang et al., 2008) and of their binding sites in the GSTA1 promoter. The differential expression in GSTA1 genotypes defined by the C-69T substitution has been attributed to an alteration of the Sp1 transcription factor (Tijhuis et al., 2005) . c-Jun participates in transducing chemical stresses like chemopreventive blocking agents (Hayes and McMahon, 2001 ). Therefore, these TFs may be potential drug targets worthy of further characterization.
